1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators

US9096603B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Riccardo Giovannini · Verona, IT
• Cornelia Dorner-Ciossek · Ingelheim am Rhein, DE
• Christian Eickmeier · Mittelbiberach, DE
• Dennis Fiegen · Biberach an der Riß, DE
• Thomas Fox · Biberach, DE
• Klaus Fuchs · Ingelheim am Rhein, DE
• Niklas Heine · Eberhardzell, DE
• Holger Rosenbrock · Mittelbiberach, DE
• Gerhard Schaenzle · Biberach, DE

Key dates

• Filing date: Nov 12, 2013
• Grant date: Aug 4, 2015
• Expiry date: Nov 15, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, wherein i.) the nitrogen atom of the pyrazolo-group that is next to the pyrimidino-group is attached to a non-aromatic, organic heterocycle having at least one ring hetero atom selected from O, N and S and ii.) to the C-atom between the two nitrogen atoms of the pyrimidinone-ring a second substituent is bound via an optionally substituted methylene-bridge. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.